{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363388845891796608.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1056/nejmoa0708379"}},{"identifier":{"@type":"URI","@value":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0708379"}}],"dc:title":[{"@value":"Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383388845891796609","@type":"Researcher","foaf:name":[{"@value":"Hans-Henrik Parving"}]},{"@id":"https://cir.nii.ac.jp/crid/1383388845891796612","@type":"Researcher","foaf:name":[{"@value":"Frederik Persson"}]},{"@id":"https://cir.nii.ac.jp/crid/1383388845891796608","@type":"Researcher","foaf:name":[{"@value":"Julia B. Lewis"}]},{"@id":"https://cir.nii.ac.jp/crid/1383388845891796610","@type":"Researcher","foaf:name":[{"@value":"Edmund J. Lewis"}]},{"@id":"https://cir.nii.ac.jp/crid/1383388845891796611","@type":"Researcher","foaf:name":[{"@value":"Norman K. Hollenberg"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00284793"},{"@type":"EISSN","@value":"15334406"}],"prism:publicationName":[{"@value":"New England Journal of Medicine"}],"dc:publisher":[{"@value":"Massachusetts Medical Society"}],"prism:publicationDate":"2008-06-05","prism:volume":"358","prism:number":"23","prism:startingPage":"2433","prism:endingPage":"2446"},"reviewed":"false","url":[{"@id":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0708379"}],"createdAt":"2008-06-04","modifiedAt":"2019-05-11","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004233405725952","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004234890435968","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice"}]},{"@id":"https://cir.nii.ac.jp/crid/1360005518347767040","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185700571392","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Effects of Aliskiren‐Based Therapy on Ambulatory Blood Pressure Profile, Central Hemodynamics, and Arterial Stiffness in Nondiabetic Mild to Moderate Hypertensive Patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567186750836224","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848658394795008","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Greater reductions in plasma aldosterone with aliskiren in hypertensive patients with higher soluble (Pro)renin receptor level"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848661366134528","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Attenuation of Brain Damage and Cognitive Impairment by Direct Renin Inhibition in Mice With Chronic Cerebral Hypoperfusion"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848664422074112","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Addition of Aliskiren to Angiotensin Receptor Blocker Improves Ambulatory Blood Pressure Profile and Cardiorenal Function Better than Addition of Benazepril in Chronic Kidney Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205095827072","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The Influence of a Direct Renin Inhibitor on the Central Blood Pressure"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205180025344","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Add-On Aliskiren Elicits Stronger Renoprotection Than High-Dose Valsartan in Type 2 Diabetic KKAy Mice That Do Not Respond to Low-Dose Valsartan"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205367420032","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"糖尿病とレニン・アンジオテンシン系抑制薬―レニン阻害薬を含めて―"},{"@language":"en","@value":"S10-5. Renin-Angiotensin Inhibitor against Diabetes Mellitus"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206445529728","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Kidney Disease and Mineralocorticoid Receptor"},{"@language":"ja","@value":"腎臓病とミネラロコルチコイド受容体"},{"@value":"医学と医療の最前線 腎臓病とミネラロコルチコイド受容体"},{"@language":"ja-Kana","@value":"イガク ト イリョウ ノ サイゼンセン ジンゾウビョウ ト ミネラロコルチコイド ジュヨウタイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206447116160","@type":"Article","resourceType":"other","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"2. Therapeutic Strategy for Diabetic Nephropathy"},{"@language":"ja","@value":"2．糖尿病腎症に対する治療戦略"},{"@value":"教育講演 糖尿病腎症の治療戦略"},{"@language":"ja-Kana","@value":"キョウイク コウエン トウニョウビョウジンショウ ノ チリョウ センリャク"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679252924800","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The pharmacological profile and clinical findings on aliskiren (Rasilez tablet), direct renin inhibitor"},{"@language":"ja","@value":"直接的レニン阻害薬アリスキレン（ラジレス）の薬理学的特長および臨床試験成績"},{"@value":"新薬紹介総説 直接的レニン阻害薬アリスキレン(ラジレス)の薬理学的特長および臨床試験成績"},{"@language":"ja-Kana","@value":"シンヤク ショウカイ ソウセツ チョクセツテキ レニン ソガイヤク アリスキレン ラジレス ノ ヤクリガクテキ トクチョウ オヨビ リンショウ シケン セイセキ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680155737984","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Renin–Angiotensin System, Hypertension, and Chronic Kidney Disease: Pharmacogenetic Implications"},{"@value":"Renin^|^ndash;Angiotensin System, Hypertension, and Chronic Kidney Disease: Pharmacogenetic Implications"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680156305536","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"New Approaches to Blockade of the Renin-Angiotensin-Aldosterone System: Characteristics and Usefulness of the Direct Renin Inhibitor Aliskiren"},{"@value":"Characteristics and usefulness of the direct renin inhibitor aliskiren"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680232197504","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Successful Treatment of Hypertension in Anuric Hemodialysis Patients with a Direct Renin Inhibitor, Aliskiren"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680492892288","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A Paradigm Shift for the Concept of Diabetic Nephropathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681411157120","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"レニン阻害剤"},{"@language":"en","@value":"Calcium Channel BlockersDirect Renin Inhibitors (DRI) as Novel Antihypertensive Agents"},{"@language":"ja-Kana","@value":"レニン ソガイザイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681426602368","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"III．治療のポイント―生活習慣の修正と降圧薬治療"},{"@language":"en","@value":"III. Key Points of Antihypertensive Treatment-life-style Modification and Drug Therapy"},{"@value":"治療のポイント : 生活習慣の修正と降圧薬治療"},{"@language":"ja-Kana","@value":"チリョウ ノ ポイント : セイカツ シュウカン ノ シュウセイ ト コウアツヤク チリョウ"}]},{"@id":"https://cir.nii.ac.jp/crid/2050870367074157184","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin Ⅰ and Ⅱ in human renin angiotensinogen transgenic mice with high salt loading"}]},{"@id":"https://cir.nii.ac.jp/crid/2051151842050541312","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Local delivery of a direct renin inhibitor into the kidney ameliorates progression of experimental glomerulonephritis"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1056/nejmoa0708379"},{"@type":"CROSSREF","@value":"10.1038/hr.2011.136_references_DOI_Oz8UgRYMvc2XuBOWpl5fxRg43ER"},{"@type":"CROSSREF","@value":"10.1254/jphs.12r03cr_references_DOI_Oz8UgRYMvc2XuBOWpl5fxRg43ER"},{"@type":"CROSSREF","@value":"10.1038/s41440-019-0284-9_references_DOI_Oz8UgRYMvc2XuBOWpl5fxRg43ER"},{"@type":"CROSSREF","@value":"10.2169/naika.100.2592_references_DOI_Oz8UgRYMvc2XuBOWpl5fxRg43ER"},{"@type":"CROSSREF","@value":"10.3999/jscpt.41.61s_references_DOI_Oz8UgRYMvc2XuBOWpl5fxRg43ER"},{"@type":"CROSSREF","@value":"10.1007/s10157-012-0601-y_references_DOI_Oz8UgRYMvc2XuBOWpl5fxRg43ER"},{"@type":"CROSSREF","@value":"10.1254/fpj.135.159_references_DOI_Oz8UgRYMvc2XuBOWpl5fxRg43ER"},{"@type":"CROSSREF","@value":"10.2185/jrm.6.26_references_DOI_Oz8UgRYMvc2XuBOWpl5fxRg43ER"},{"@type":"CROSSREF","@value":"10.1111/j.1751-7176.2012.00640.x_references_DOI_Oz8UgRYMvc2XuBOWpl5fxRg43ER"},{"@type":"CROSSREF","@value":"10.1186/1755-1536-4-25_references_DOI_Oz8UgRYMvc2XuBOWpl5fxRg43ER"},{"@type":"CROSSREF","@value":"10.1272/jnms.80.25_references_DOI_Oz8UgRYMvc2XuBOWpl5fxRg43ER"},{"@type":"CROSSREF","@value":"10.2169/naika.98.2894_references_DOI_Oz8UgRYMvc2XuBOWpl5fxRg43ER"},{"@type":"CROSSREF","@value":"10.1254/jphs.10r04fm_references_DOI_Oz8UgRYMvc2XuBOWpl5fxRg43ER"},{"@type":"CROSSREF","@value":"10.1007/s10157-013-0893-6_references_DOI_Oz8UgRYMvc2XuBOWpl5fxRg43ER"},{"@type":"CROSSREF","@value":"10.1038/s41440-018-0037-1_references_DOI_Oz8UgRYMvc2XuBOWpl5fxRg43ER"},{"@type":"CROSSREF","@value":"10.1161/hypertensionaha.111.173534_references_DOI_Oz8UgRYMvc2XuBOWpl5fxRg43ER"},{"@type":"CROSSREF","@value":"10.3390/ijms140815361_references_DOI_Oz8UgRYMvc2XuBOWpl5fxRg43ER"},{"@type":"CROSSREF","@value":"10.1254/jphs.12031fp_references_DOI_Oz8UgRYMvc2XuBOWpl5fxRg43ER"},{"@type":"CROSSREF","@value":"10.1097/hjh.0b013e328338bb11_references_DOI_Oz8UgRYMvc2XuBOWpl5fxRg43ER"},{"@type":"CROSSREF","@value":"10.14789/jmj.60.293_references_DOI_Oz8UgRYMvc2XuBOWpl5fxRg43ER"},{"@type":"CROSSREF","@value":"10.4264/numa.73.14_references_DOI_Oz8UgRYMvc2XuBOWpl5fxRg43ER"},{"@type":"CROSSREF","@value":"10.2169/naika.104.218_references_DOI_Oz8UgRYMvc2XuBOWpl5fxRg43ER"}]}